lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways

Saleh, Raed Obaid; Al-Ouqaili, Mushtak T. S.; Ali, Eyhab; Alhajlah, Sharif; Kareem, Anaheed Hussein; Shakir, Maha Noori; Alasheqi, Mohammed Qasim; Mustafa, Yasser Fakri; Alawadi, Ahmed; Alsaalamy, Ali

doi:10.1007/s12032-023-02263-8

Cited by 9 publications

(2 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, Keerthi proved that matrisome genes were seen to affect survival across cancers by a pan-cancer analysis [ 54 ]. Furthermore, these proteins were involved in several classical signaling pathways that have been proven to play important roles in tumors, such as the Wnt signaling pathway, Hippo signaling pathway, and mTOR signaling pathway [ 55 ].…”

Section: Discussionmentioning

confidence: 99%

CTHRC1 is a prognostic biomarker correlated with immune infiltration in head and neck squamous cell carcinoma

Zhang,

Ren,

Wang

et al. 2024

BMC Oral Health

View full text Add to dashboard Cite

Background Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide, characterized by high morbidity, high mortality, and poor prognosis. Collagen triple helix repeat containing 1 (CTHRC1) has been shown to be highly expressed in various cancers. However, its biological functions, potential role as a biomarker, and its relationship with immune infiltrates in HNSCC remain unclear. Our principal objective was to analyze CTHRC1 expression, its prognostic implications, biological functions, and its effects on the immune system in HNSCC patients using bioinformatics analysis. Methods The expression matrix was obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). CTHRC1 expression in HNSCC was analyzed between tumor and adjacent normal tissues, different stages were compared, and its impact on clinical prognosis was assessed using Kaplan-Meier analysis. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Variation Analysis (GSVA) were employed for enrichment analysis. The Search Tool for the Retrieval of Interacting Genes database (STRING) was used to analyze protein-protein interactions. Pearson correlation tests were used to investigate the association between CTHRC1 expression and immune checkpoints. The correlation between CTHRC1 and immune infiltration was investigated using CIBERSORT, TIMER, and ESTIMATE. Results Compared to adjacent normal tissues, CTHRC1 was found to be highly overexpressed in tumors. Increased expression of CTHRC1 was more evident in the advanced stage of HNSCC and predicted a poor prognosis. Most genes related to CTHRC1 in HNSCC were enriched in physiological functions of Extracellular matrix(ECM) and tumor. Furthermore, several immune checkpoints, such as TNFSF4 and CD276 have been shown to be associated with CTHRC1 expression. Notably, the level of CTHRC1 expression correlated significantly with immune infiltration levels, particularly activated macrophages in HNSCC. Conclusions High expression of CTHRC1 predicts poor prognosis and is associated with immune infiltration in HNSCC, confirming its utility as a tumor marker for HNSCC. Trial registration Not applicable. All data are from public databases and do not contain any clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

CTHRC1 is a prognostic biomarker correlated with immune infiltration in head and neck squamous cell carcinoma

Zhang,

Ren,

Wang

et al. 2024

BMC Oral Health

View full text Add to dashboard Cite

show abstract

“…The evolution of resistance and issues related to drug specificity underscore the need for a dynamic and adaptable approach in precision medicine implementation against colorectal cancer. Continuous monitoring of a patient’s molecular profile throughout the course of treatment, incorporating real-time data, and utilizing advanced diagnostic technologies become crucial components of a successful precision medicine strategy. , Additionally, the integration of multiomics approaches, combining genomics, proteomics, and metabolomics, offers a more comprehensive understanding of the molecular landscape, aiding in the identification of potential resistance mechanisms and refining drug specificity . Collaborative efforts among researchers, clinicians, and pharmaceutical industries are essential for addressing these challenges.…”

Section: Challenges and Considerations In Precision Medicine Implemen...mentioning

confidence: 99%

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Kiran,

Yashaswini,

Maheshwari

et al. 2024

ACS Pharmacol. Transl. Sci.

View full text Add to dashboard Cite

Precision medicine is transforming colorectal cancer treatment through the integration of advanced technologies and biomarkers, enhancing personalized and effective disease management. Identification of key driver mutations and molecular profiling have deepened our comprehension of the genetic alterations in colorectal cancer, facilitating targeted therapy and immunotherapy selection. Biomarkers such as microsatellite instability (MSI) and DNA mismatch repair deficiency (dMMR) guide treatment decisions, opening avenues for immunotherapy. Emerging technologies such as liquid biopsies, artificial intelligence, and machine learning promise to revolutionize early detection, monitoring, and treatment selection in precision medicine. Despite these advancements, ethical and regulatory challenges, including equitable access and data privacy, emphasize the importance of responsible implementation. The dynamic nature of colorectal cancer, with its tumor heterogeneity and clonal evolution, underscores the necessity for adaptive and personalized treatment strategies. The future of precision medicine in colorectal cancer lies in its potential to enhance patient care, clinical outcomes, and our understanding of this intricate disease, marked by ongoing evolution in the field. The current reviews focus on providing in-depth knowledge on the various and diverse approaches utilized for precision medicine against colorectal cancer, at both molecular and biochemical levels.

show abstract

Lipid Nanoparticle (LNP) ‐A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC)

Zhang,

Guo,

Yuan

et al. 2024

Global Challenges

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) stands as the predominant form of primary liver cancer, characterized by a dismal prognosis. Therapeutic options for advanced HCC remain sparse, with efficacy significantly hampered by the emergence of drug resistance. In parallel with research into novel pharmacological agents, advances in drug delivery systems represent a promising avenue for overcoming resistance. Lipid nanoparticles (LNPs) have demonstrated considerable efficacy in the delivery of nucleic acid‐based therapeutics and hold potential for broader applications in drug delivery. This review describes the development of LNPs tailored for HCC treatment and consolidates recent investigations using LNPs to target HCC.

show abstract

lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways

Cited by 9 publications

References 132 publications

CTHRC1 is a prognostic biomarker correlated with immune infiltration in head and neck squamous cell carcinoma

CTHRC1 is a prognostic biomarker correlated with immune infiltration in head and neck squamous cell carcinoma

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies

Lipid Nanoparticle (LNP) ‐A Vector Suitable for Evolving Therapies for Advanced Hepatocellular Carcinoma (HCC)

Contact Info

Product

Resources

About